04 July 2024, Brussels – EuropaBio’s 2024 Annual General Meeting (AGM) held on the 27^th of June celebrated the EU recognition of the significance of biotechnology, looking ahead for its leading position within the priorities for the upcoming Commission mandate. The AGM also welcomed new Board representatives across sectors and new Members, reflecting the expansion of biotechnology across ecosystems.

EuropaBio welcomes the 8 new board members approved during the AGM. These new members bring leadership from across their respective sectors within biotechnology, and will prove invaluable in guiding the association going forward.

• Mr Boris Azaïs representing MSD,
• Mr Stefaan Fiers representing Takeda Belgium,
• Dr Sinead Keogh representing BioPharmaChemical Ireland,
• Mr Matthew Lloyd-Watkins representing Pfizer,
• Mr Wojciech Nowak representing Novartis International,
• Mr Colin O’Donnell representing Alexion, AstraZeneca Rare Disease,
• Mrs Sanne Verhoeven representing Corbion,
• Dr Eva Wilke representing BASF.

In addition to being approved to the Board, EuropaBio confirmed the approval of Mr Wojciech Nowak as the Chair of the Healthcare Biotechnology Council.

13 new member companies and associations were confirmed during the AGM, expanding the diverse set of members contributing to the biotechnology ecosystem in Europe. EuropaBio welcomes LanzaTech, Syensqo, Biocatalyst Foundation, Genopole, Prague.bio, DNA Script, Formo, Gourmey, Probiotic Group, Standing Ovation, WHC Lab, SICOS and X.DeepTech.

Following the close of the meeting, Dr Claire Skentelbery, Director General of EuropaBio commented “We are at a pivotal moment for biotechnology within its commercial delivery for Europe, and we are delighted to see the recognition of its significance as it builds upon Europe’s excellent research foundations.”